Drug Trial Radar · NCT07489209
A Dose-exploration Study of EDP167 in HoFH
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 6, 2026
Primary completion
Oct 4, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Eddingpharm (Zhuhai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.
Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
EDP167Drug
EDP167 sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at week 24 of the main study phase.Time frame: Up to week 24 of the main study phase
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.